Cannabinoids for Osteoarthritis

(COPE Trial)

Recruiting at 2 trial locations

Overseen By Deep Grewal

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University Health Network, Toronto

Trial Summary

What is the purpose of this trial?

This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy. The goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and/or knee osteoarthritis. Participants will: * Take either CBD, THC, or a placebo capsule daily for 8 weeks * Complete follow-ups remotely, with no in-person clinic visits required * Maintain a diary tracking their study drug usage and any additional pain medications

Research Team

Dr. Hance Clarke, MD

Principal Investigator

University Health Network, Toronto

Eligibility Criteria

This trial is for individuals with osteoarthritis, specifically in the hip or knee. Participants will take a daily capsule of either CBD, THC, or a placebo for 8 weeks and track their pain medication use. The study requires remote follow-ups.

Inclusion Criteria

I experience significant pain that affects my daily activities.

I haven't started any new pain or arthritis treatments in the last month.

I can read, understand, and speak English or French.

Exclusion Criteria

A history of diagnosed cannabis use disorder or dependence

Active substance use disorder

Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout)

Treatment Details

Interventions

• Cannabis Extracts (Cannabinoids)

Trial Overview The study tests the effectiveness of oral cannabis extracts (CBD and THC) versus a placebo in managing osteoarthritis pain. It aims to determine if these treatments can be alternatives to current options with limited success and side effects.

Participant Groups

Group I: THC (∆9-tetrahydrocannabinol) Experimental Treatment 1 Intervention

Each capsule contains a concentration of 3 mg of ∆9-tetrahydrocannabinol (THC). Participants will receive THC capsules for a total duration of 8 weeks.

Group II: CBD (Cannabidiol) Experimental Treatment 1 Intervention

Each capsule contains a concentration of 50 mg of Cannabidiol (CBD). Participants will receive CBD for a total duration of 8 weeks.

Group III: Placebo Placebo Group 1 Intervention

Participants will receive matching placebo capsules for a total duration of 8 weeks.

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials

1,555

Recruited

526,000+

Canadian Institutes of Health Research (CIHR)

Collaborator

Trials

1,417

Recruited

26,550,000+